ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January
ScripBig pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab
Scrip“Either for young biotech or established pharma companies in China, a combination of innovation and globalization is the trend,” Shan Jiang, chief technology officer at Hansoh Pharmaceutical, told the
ScripA newly approved, homegrown once-weekly GLP-1 receptor agonist is seeking to disrupt a diabetes space in China currently dominated by Novo Nordisk’s same-class global blockbuster Ozempic (semaglutide)